Kato M, Schleimer R P
Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland 21224.
Lung. 1994;172(2):113-24. doi: 10.1007/BF00185082.
Granulocyte/macrophage colony-stimulating factor (GM-CSF) is an important hematopoietic growth factor which has been shown to induce proliferation and activation of inflammatory cells, and may play a role in allergic diseases and experimental allergic reactions. Since little is known about the involvement of cytokines in allergic inflammation in the lung, we investigated whether human lung fragments produce GM-CSF in vitro. The present studies demonstrate that human lung fragments produce GM-CSF in vitro and that glucocorticoids are potent inhibitors of this cytokine production. Human lung was cut into fragments, rinsed, and cultured in 60-mm tissue culture plates containing 50 mg of tissue in RPMI 1640 with antibiotics in the presence or absence of a variety of steroids for 18 h. Lung fragments were rinsed and then incubated for an additional 4 h. Supernatants were harvested and analyzed for GM-CSF activity using the GM-CSF/interleukin (IL)-3 responsive M-07e human leukemic cell line. Steroids alone had no effect on M-07e proliferation. Human lung fragments produced 32.1 +/- 11.8 ng of GM-CSF equivalents per gram wet weight of tissue during the 4 h incubation (mean +/- S.E.M., n = 5, range 9.2-74.2). While specific antisera against human GM-CSF neutralized 96.8 +/- 2.8% (n = 5) of the activity, anti-IL-3 antibody had no effect, suggesting most or all of this activity was GM-CSF. Treatment of lung fragments in vitro for 18 h with hydrocortisone (HC) inhibited the production of GM-CSF dose-dependently. Maximal inhibition of GM-CSF production was 72.8 +/- 4.0% at a concentration of 10(-6) M hydrocortisone (n = 5), and the molar concentration of HC that inhibited of GM-CSF production by lung tissue by 50% (IC50) was approximately 4.5 x 10(-7) M. Kinetic studies revealed that a 6 h preincubation with the drug was required for 50% inhibition of GM-CSF production. HC and other glucocorticoids, at a concentration of 0.1 microM, demonstrated significant inhibition of GM-CSF release. Based on the rank order of potency of several glucocorticoids, and the fact that nonglucocorticoid steroids including testosterone and beta-estradiol (0.1 microM) had no effect, we suggest that this is a specific receptor-mediated effect. We conclude that human lung produces GM-CSF in vitro and that antiinflammatory steroids are potent and effective inhibitors of the production of this cytokine. This may contribute to the therapeutic efficacy of these drugs in pulmonary diseases.
粒细胞/巨噬细胞集落刺激因子(GM-CSF)是一种重要的造血生长因子,已被证明可诱导炎症细胞的增殖和活化,并可能在过敏性疾病和实验性过敏反应中发挥作用。由于对细胞因子在肺部过敏性炎症中的作用了解甚少,我们研究了人肺组织碎片在体外是否产生GM-CSF。目前的研究表明,人肺组织碎片在体外可产生GM-CSF,且糖皮质激素是这种细胞因子产生的有效抑制剂。将人肺切成碎片,冲洗后,置于含有50mg组织的60mm组织培养板中,在RPMI 1640培养基中,添加抗生素,在有或没有各种类固醇的情况下培养18小时。肺组织碎片冲洗后再孵育4小时。收集上清液,使用GM-CSF/白细胞介素(IL)-3反应性M-07e人白血病细胞系分析GM-CSF活性。单独的类固醇对M-07e细胞增殖没有影响。在4小时的孵育过程中,人肺组织碎片每克湿重组织产生32.1±11.8ng GM-CSF当量(平均值±标准误,n = 5,范围9.2 - 74.2)。虽然针对人GM-CSF的特异性抗血清中和了96.8±2.8%(n = 5)的活性,但抗IL-3抗体没有作用,这表明大部分或所有这种活性都是GM-CSF。用氢化可的松(HC)在体外处理肺组织碎片18小时,剂量依赖性地抑制了GM-CSF的产生。在氢化可的松浓度为10^(-6)M时,GM-CSF产生的最大抑制率为72.8±4.0%(n = 5),使肺组织GM-CSF产生抑制50%(IC50)的HC摩尔浓度约为4.5×10^(-7)M。动力学研究表明,药物预孵育6小时才能使GM-CSF产生受到50%的抑制。HC和其他糖皮质激素在浓度为0.1μM时,对GM-CSF释放有显著抑制作用。根据几种糖皮质激素的效力顺序,以及包括睾酮和β-雌二醇(0.1μM)在内的非糖皮质激素类固醇没有作用这一事实,我们认为这是一种特异性受体介导的效应。我们得出结论,人肺在体外产生GM-CSF,抗炎类固醇是这种细胞因子产生的强效且有效的抑制剂。这可能有助于这些药物在肺部疾病中的治疗效果。